Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Kite, A Gilead Company

Clinicaltrial registered21 Oct 2026

Kite, A Gilead Company

21 Oct 2026: Trial registered · A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
21 Oct 2026
Title
A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma
Conditions
Newly Diagnosed Multiple Myeloma
Phase
Phase 3
Study Type
Interventional
Status
Not Yet Recruiting
Reference
NCT07887672
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Kite, A Gilead Company

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Kite, A Gilead Company in our registers.

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.